Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Bone Marrow vs Peripheral Blood Grafts

J Clin Oncol; ePub 2017 Jun 23; Bashey, et al

Publish date:

Peripheral blood and bone marrow grafts can be used for haploidentical transplantation with the post-transplant cyclophosphamide approach, but patterns of treatment failure will likely differ, according to a study involving 671 individuals.

Participants with hematologic malignancies who underwent transplantation between 2009 and 2014 received either bone marrow (n=481) or peripheral blood (n=190) grafts. Investigators looked at transplant outcome differences by graft type. Among the results:

  • Hematopoietic recovery was similar in both groups.
  • Patients receiving bone marrow grafts were less likely to experience grade 2 to 4 acute and chronic graft-versus-host disease.
  • Overall survival was similar in both groups: 54% for bone marrow and 57% for peripheral blood patients.
  • Non-relapse mortality risk was also similar in both groups.
  • Relapse risk was higher after bone marrow transplantation.

Citation:

Bashey A, Zhang M, McCurdy S, et al. Mobilized peripheral blood stem cells versus unstimulated bone marrow as a graft source for T-cell–replete haploidentical donor transplantation using post-transplant cyclophosphamide. [Published online ahead of print June 23, 2017]. J Clin Oncol. doi:10.1200/JCO.2017.72.8428.

This Week's Must Reads